Document is current

Article History

Received: 24 June 2025

Revised: 15 August 2025

Accepted: 23 August 2025

First Online: 8 September 2025

Declarations

:

: Drs. Dillman, Baker, Ream, Bruining, Rieder, Fidler, Denson, and Fletcher receive grant support from The Leona M. And Harry B. Helmsley Foundation which provided partial support for this work via a grant to Drs. Dillman and Denson (co-PI’s, “Artificial Intelligence Prediction of Meaningful Outcomes in Newly Diagnosed Small Bowel Crohn’s Disease”). These authors also receive other funding from The Leona M. And Harry B. Helmsley Foundation, including grants to the Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. Dr. Fletcher is also the recipient of a research grant to the institution from Siemens Healthineers, Alimentiv, and Pfizer, all unrelated to this work. He is co-investigator with motillent. JGF is a consultant with funds to institution from Genentech, Boehringer Ingelheim, Glaxo Smith Kline, Janssen, Medtronic, Takeda, Alimentiv, Inc. Red X Pharma.Dr. Baker receives funding to the institution from Pfizer and Merck.Dr. Rieder is consultant to or on advisory board of Adiso, Adnovate, Agomab, Allergan, AbbVie, Arena, Astra Zeneca, Bausch & Lomb, Boehringer-Ingelheim, Celgene/BMS, Celltrion, CDISC, Celsius, Cowen, 89Bio, Eugit, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Granite, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis Limited, Index Pharma, Landos, Jannsen, Koutif, Mestag, Metacrine, Mirum, Mobius, Mopac, Morphic, Myka Labs, Organovo, Origo, Palisade, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Sanofi, Surmodics, Surrozen, Takeda, Techlab, Teva, Theravance, Thetis, Tr1x Bio, UCB, Ysios DHB is a consultant to Johnson & Johnson.Dr. Dillman receives unrelated research support from Bracco, GE HealthCare, Guerbet, Motilent, Perspectum, and Philips Healthcare.